Market by Type (Expanded Polytetrafluoroethylene (ePTFE), Polyurethane, Polyethylene Terephthalate (PET), Other Types) Blood Vessel Diameter (Large , Medium, Small) Patient Demographic (Adult, Pediatric) Application (Aortic Disease, Peripheral Artery, Hemodialysis) End-User (Hospital, Specialty Clinics, Ambulatory Surgical Center, Other End-User) and Regional Outlook | Forecast 2024-2032
According to Triton Market Research’s report, the Global Artificial Blood Vessels Market is expected to advance with a CAGR of 6.89% during the forecast period 2024-2032.
ARTIFICIAL BLOOD VESSELS MARKET SCOPE
Report scope can be customized per your requirements - Request Free Sample Report
ARTIFICIAL BLOOD VESSELS MARKET ANALYSIS
Artificial blood vessel materials are synthetic constructs designed to replicate the function of natural blood vessels, providing essential pathways for blood flow in cases where natural veins or arteries are damaged or diseased. Artificial veins and artificial arteries are created using various blood vessel replacement materials, including polymers and biocompatible materials, often employing advanced technologies like 3D printing artificial blood vessels. These synthetic vessels are crucial for treating cardiovascular diseases, which are the leading cause of death globally, responsible for approximately 17.9 million deaths each year, according to the World Health Organization (WHO).
The demand for artificial blood vessels is on the rise, driven by the need for reliable solutions in conditions like coronary artery disease, peripheral artery disease (PAD), and end-stage renal disease (ESRD). The growing aging population exacerbates this need, as aging significantly heightens the risk of cardiovascular diseases and vascular complications. With the global population aged 65 and over projected to nearly double by 2050, the market for synthetic vascular grafts is expanding rapidly, driven by the increasing requirement for effective, durable vascular replacements.
Click here to check out our blog on the Global Artificial Blood Vessels Market
ARTIFICIAL BLOOD VESSELS MARKET PERFORMANCE: DRIVERS, CHALLENGES, AND OPPORTUNITIES
Growing Geriatric Population and Changing Lifestyles
The increasing prevalence of cardiovascular diseases (CVDs) and vascular disorders, combined with shifting demographics and lifestyle changes, is significantly driving the demand for artificial blood vessels in the global market. As the population’s age and lifestyle-related health issues such as obesity, diabetes, and sedentary behaviors become more common, the need for effective vascular interventions and grafts is growing. These trends are leading to a higher demand for artificial blood vessels to address conditions like atherosclerosis, coronary artery disease, and peripheral artery disease.
The aging global population plays a crucial role in the rising prevalence of cardiovascular diseases and vascular disorders. According to the United Nations, the number of people aged 65 and over is expected to double from 734 million in 2020 to 1.5 billion by 2050. This demographic shift increases the susceptibility of older individuals to vascular conditions that often require surgical interventions involving artificial blood vessels. Additionally, the growing incidence of end-stage renal disease (ESRD), partly due to an aging population and higher rates of diabetes, is also contributing to the increased need for artificial blood vessels, particularly for patients undergoing hemodialysis.
Stringent Regulatory Approvals and Clinical Trial Requirements
Stringent regulatory approvals and clinical trial requirements are essential to ensure the safety and efficacy of artificial blood vessels. However, these processes can also create significant challenges in terms of time, cost, and resource allocation. Artificial blood vessels are classified as high-risk medical devices in many regulatory jurisdictions, including the United States and the European Union. This classification subjects them to rigorous scrutiny and extensive testing before they can be approved for commercial use. In the United States, for instance, the Food and Drug Administration (FDA) regulates these devices under the Premarket Approval (PMA) pathway, which requires a thorough review of preclinical and clinical data to assess safety and effectiveness.
The clinical trial requirements for artificial blood vessels are particularly demanding, often involving multiple phases that must demonstrate the device’s performance, durability, and potential for adverse events over an extended period. These trials can span several years, necessitating significant financial investment, specialized expertise, and a large patient population. Additionally, recruiting and retaining participants for these trials can be challenging due to the high-risk nature of the procedures involved. The complexity and length of these trials add to the overall cost and time required for bringing artificial blood vessels to market, posing significant barriers for manufacturers.
Development of 3D Bioprinting Techniques for Customized Vascular Grafts
Artificial blood vessels have traditionally relied on synthetic materials or cadaveric vessels, which can present limitations such as reduced durability and an increased risk of complications. However, advances in 3D bioprinting techniques provide an alternative by enabling the creation of patient-specific, biocompatible vascular grafts that are tailored to individual anatomical needs. For example, researchers at the University of Minnesota successfully bioprinted a life-sized model of a patient’s cardiovascular system, paving the way for the production of customized vascular grafts that closely mimic the structures and properties of natural blood vessels.
Another notable development is a collaborative project between the University of Toronto and the Hospital for Sick Children, where researchers used 3D bioprinting to create living vascular grafts by depositing patient-derived cells onto a biodegradable scaffold. This method facilitates seamless integration with the recipient’s body, offering a more personalized and potentially more successful treatment option. The main advantage of 3D bioprinting lies in its ability to replicate the complex geometries and anatomical features of blood vessels with precision. By using advanced imaging techniques and patient-specific data, bioprinted vascular grafts can be customized to fit the unique vascular anatomy of each recipient, potentially reducing the risk of complications and improving surgical outcomes.
GLOBAL ARTIFICIAL BLOOD VESSELS MARKET REPORT SEGMENTATION
• Market by Type:
o Expanded Polytetrafluoroethylene (ePTFE)
o Polyurethane
o Polyethylene Terephthalate (PET)
o Other Types
Expanded Polytetrafluoroethylene
(ePTFE) is a synthetic fluoropolymer used in artificial blood vessels. Its
microporous structure, consisting of interconnected nodes and fibrils, supports
tissue ingrowth and improves biocompatibility. This structure allows ePTFE to
mimic the properties of natural blood vessels, promoting blood flow and
reducing the risk of thrombosis or occlusion. It is chemically resistant,
making it inert to bodily fluids and substances, which helps ensure its
durability in long-term implants. It also has tensile strength and flexibility,
allowing it to endure the pressures of the cardiovascular system. Manufacturing
techniques like stretching, sintering, and surface modifications are employed
to enhance the surface characteristics of ePTFE grafts.
• Market by Blood
Vessel Diameter:
o Large
o Medium
o Small
Large artificial blood vessel
grafts, which typically range in diameter from 6 mm to 30 mm or more, are
designed to replace or bypass major blood vessels such as the aorta, iliac
arteries, or femoral arteries. These grafts are constructed to handle the pressures
and flow rates associated with the cardiovascular system’s larger vessels. They
are often employed in procedures like aortic aneurysm repair, where a portion
of the aorta is substituted with a synthetic graft. The selection of the
appropriate graft material and design for large blood vessel applications is
influenced by factors such as the specific location and diameter of the vessel
being replaced, expected blood flow rates and pressures, and the patient’s
characteristics.
• Market by Patient
Demographics:
o Adult
o Pediatric
• Market by
Application:
o Aortic Disease
o Peripheral Artery
o Hemodialysis
• Market by End-User:
o Hospital
o Specialty Clinics
o Ambulatory Surgical Center
o Other End-User
MARKET BY REGION:
• North America: United States and Canada
• Europe: United Kingdom, Germany, France, Spain, Italy, Poland, and Rest of Europe
• Asia-Pacific: China, Japan, India, South Korea, ASEAN Countries, Australia & New Zealand, and Rest of Asia-Pacific
• Latin America: Brazil, Mexico, and Rest of Latin America,
• Middle East and Africa: United Arab Emirates, Saudi Arabia, Israel, South Africa, and Rest of Middle East & Africa
KEY ARTIFICIAL BLOOD VESSELS COMPANIES INSIGHTS
The companies’ insights help dive into data about the key players in the artificial blood vessels market. The strategic initiatives for each of the companies considered have been covered in detail. Some of the key strategic initiatives are:
Acquisition (January 2020): Getinge and Applikon Biotechnology
In January 2020, Getinge acquired Applikon Biotechnology, a company specializing in the development and supply of advanced bioreactor systems for the research and production of vaccines and antibodies in the biopharmaceutical industry, as well as enzymes and bio-plastics for industrial biotechnology.
Acquisition (December 2021): Becton, Dickinson and Company and Venclose Inc
Becton, Dickinson and Company acquired Venclose Inc, expanding its portfolio to include solutions for chronic venous insufficiency (CVI) treatment. Venclose’s Radio Frequency (RF) ablation technology platform addressed a significant therapeutic need, impacting up to 40% of women and 17% of men in the United States.
KEY BENEFITS OF THE REPORT:
Triton Market Research has a collective experience of 25-30 years in the industry, with its analysts and experts encompassing the most infallible research methodology for its market intelligence and industry analysis.
Our research methodology helps in achieving a broader consensus of the market size, shape, and industry trends within each industry segment.
The strategy adopted in designing the research methodology includes the amalgamation of the information assembled from primary and secondary sources, with the assistance of analytical tools to construct the forecast and predictive models.
The scope of the market report comprises the current scenario of the global artificial blood vessels market, along with a detailed overview of the industry outlook, market dynamics, segmentation analysis, regional outlook, and competitive landscape for the period 2023-2030.
FAQs:
Q1) How long do artificial blood vessels last?
The lifespan varies depending on the material and application, but they are generally designed to last for many years, though complications like clotting or infection can affect longevity.
Q2) Are artificial blood vessels a permanent solution?
In many cases, they are intended to be permanent, but some may require replacement or additional interventions over time.
Q3) How is the body’s immune response managed with artificial blood vessels?
Synthetic materials are chosen to minimize immune response, and some bioengineered vessels use the patient’s cells to reduce the risk of rejection.
Q4) Which years does the artificial blood vessels market cover?
Our report explores the historical data of the artificial blood vessels market for the years 2020, 2021, 2022, and 2023. Additionally, the report provides a forecast of the market size from 2024 to 2032, with 2023 as the base year.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. GLOBAL ARTIFICIAL BLOOD VESSELS MARKET –
SUMMARY
2. INDUSTRY OUTLOOK
2.1. PORTER’S FIVE FORCES ANALYSIS
2.1.1. THREAT OF NEW ENTRANTS
2.1.2. THREAT OF SUBSTITUTES
2.1.3. BARGAINING POWER OF BUYERS
2.1.4. BARGAINING POWER OF SUPPLIERS
2.1.5. THREAT OF COMPETITIVE RIVALRY
2.2. MARKET MATURITY ANALYSIS
2.3. SUPPLY CHAIN ANALYSIS
2.3.1. RAW MATERIALS
2.3.2. MANUFACTURERS
2.3.3. DISTRIBUTORS
2.3.4. END-USER
2.4. REGULATORY FRAMEWORK
2.5. KEY BUYING IMPACT ANALYSIS
2.5.1. BIOCOMPATIBILITY
2.5.2. DURABILITY AND LONGEVITY
2.5.3. CUSTOMIZATION AND VERSATILITY
2.5.4. REGULATORY COMPLIANCE AND QUALITY ASSURANCE
2.6. KEY MARKET STRATEGIES
2.6.1. COLLABORATIONS
2.6.2. PRODUCT LAUNCHES
2.6.3. ACQUISITIONS
2.6.4. BUSINESS DIVESTITURES & EXPANSIONS
2.7. MARKET DRIVERS
2.7.1. RISING RATES OF CARDIOVASCULAR DISEASES AND
VASCULAR DISORDERS
2.7.2. DEVELOPMENTS IN TISSUE ENGINEERING AND
REGENERATIVE MEDICINE
2.7.3. AGING POPULATION AND SHIFTING LIFESTYLES
2.8. MARKET CHALLENGES
2.8.1. EXPENSES IN THE DEVELOPMENT AND
COMMERCIALIZATION OF ARTIFICIAL BLOOD VESSELS
2.8.2. STRICT REGULATORY APPROVALS AND CLINICAL
TRIAL REQUIREMENTS
2.8.3. CHALLENGES RELATED TO BIOCOMPATIBILITY AND
LONG-TERM DURABILITY
2.9. MARKET OPPORTUNITIES
2.9.1. ADVANCEMENTS IN 3D BIOPRINTING FOR TAILORED
VASCULAR GRAFTS
2.9.2. USE OF NANOTECHNOLOGY AND BIOMIMETIC
MATERIALS TO ENHANCE FUNCTIONALITY
2.10. ANALYST PERSPECTIVE
3. GLOBAL ARTIFICIAL BLOOD VESSELS MARKET – BY TYPE
3.1. EXPANDED POLYTETRAFLUOROETHYLENE (EPTFE)
3.2. POLYETHYLENE TEREPHTHALATE (PET)
3.3. POLYURETHANE
3.4. OTHER TYPES
4. GLOBAL ARTIFICIAL BLOOD VESSELS MARKET – BY BLOOD
VESSEL DIAMETER
4.1. LARGE
4.2. MEDIUM
4.3. SMALL
5. GLOBAL ARTIFICIAL BLOOD VESSELS MARKET – BY
PATIENT DEMOGRAPHIC
5.1. PEDIATRIC
5.2. ADULT
6. GLOBAL ARTIFICIAL BLOOD VESSELS MARKET – BY APPLICATION
6.1. PERIPHERAL ARTERY
6.2. HEMODIALYSIS
6.3. AORTIC DISEASE
7. GLOBAL ARTIFICIAL BLOOD VESSELS MARKET – BY END-USER
7.1. HOSPITAL
7.2. SPECIALTY CLINIC
7.3. AMBULATORY SURGICAL CENTER
7.4. OTHER END-USERS
8. GLOBAL ARTIFICIAL BLOOD VESSELS MARKET – BY
REGIONAL OUTLOOK
8.1. NORTH AMERICA
8.1.1. MARKET BY TYPE
8.1.2. MARKET BY BLOOD VESSEL DIAMETER
8.1.3. MARKET BY PATIENT DEMOGRAPHIC
8.1.4. MARKET BY APPLICATION
8.1.5. MARKET BY END-USER DIAMETER
8.1.6. COUNTRY ANALYSIS
8.1.6.1. UNITED STATES
8.1.6.1.1. UNITED STATES ARTIFICIAL
BLOOD VESSELS MARKET FORECAST & PROSPECTS
8.1.6.2. CANADA
8.1.6.2.1. CANADA ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.2. EUROPE
8.2.1. MARKET BY TYPE
8.2.2. MARKET BY BLOOD VESSEL DIAMETER
8.2.3. MARKET BY PATIENT DEMOGRAPHIC
8.2.4. MARKET BY APPLICATION
8.2.5. MARKET BY END-USER DIAMETER
8.2.6. COUNTRY ANALYSIS
8.2.6.1. UNITED KINGDOM
8.2.6.1.1. UNITED KINGDOM ARTIFICIAL
BLOOD VESSELS MARKET FORECAST & PROSPECTS
8.2.6.2. GERMANY
8.2.6.2.1. GERMANY ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.2.6.3. FRANCE
8.2.6.3.1. FRANCE ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.2.6.4. SPAIN
8.2.6.4.1. SPAIN ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.2.6.5. ITALY
8.2.6.5.1. ITALY ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.2.6.6. POLAND
8.2.6.6.1. POLAND ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.2.6.7. REST OF EUROPE
8.2.6.7.1. REST OF EUROPE ARTIFICIAL
BLOOD VESSELS MARKET FORECAST & PROSPECTS
8.3. ASIA-PACIFIC
8.3.1. MARKET BY TYPE
8.3.2. MARKET BY BLOOD VESSEL DIAMETER
8.3.3. MARKET BY PATIENT DEMOGRAPHIC
8.3.4. MARKET BY APPLICATION
8.3.5. MARKET BY END-USER DIAMETER
8.3.5.1. CHINA
8.3.5.1.1. CHINA ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.3.5.2. JAPAN
8.3.5.2.1. JAPAN ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.3.5.3. INDIA
8.3.5.3.1. INDIA ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.3.5.4. SOUTH KOREA
8.3.5.4.1. SOUTH KOREA ARTIFICIAL
BLOOD VESSELS MARKET FORECAST & PROSPECTS
8.3.5.5. ASEAN COUNTRIES
8.3.5.5.1. ASEAN COUNTRIES ARTIFICIAL
BLOOD VESSELS MARKET FORECAST & PROSPECTS
8.3.5.6. AUSTRALIA & NEW
ZEALAND
8.3.5.6.1. AUSTRALIA & NEW
ZEALAND ARTIFICIAL BLOOD VESSELS MARKET FORECAST & PROSPECTS
8.3.5.7. REST OF ASIA-PACIFIC
8.3.5.7.1. REST OF ASIA-PACIFIC ARTIFICIAL
BLOOD VESSELS MARKET FORECAST & PROSPECTS
8.4. LATIN AMERICA
8.4.1. MARKET BY TYPE
8.4.2. MARKET BY BLOOD VESSEL DIAMETER
8.4.3. MARKET BY PATIENT DEMOGRAPHIC
8.4.4. MARKET BY APPLICATION
8.4.5. MARKET BY END-USER DIAMETER
8.4.6. COUNTRY ANALYSIS
8.4.6.1. BRAZIL
8.4.6.1.1. BRAZIL ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.4.6.2. MEXICO
8.4.6.2.1. MEXICO ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.4.6.3. REST OF LATIN AMERICA
8.4.6.3.1. REST OF LATIN AMERICA ARTIFICIAL
BLOOD VESSELS MARKET FORECAST & PROSPECTS
8.5. MIDDLE EAST AND AFRICA
8.5.1. MARKET BY TYPE
8.5.2. MARKET BY BLOOD VESSEL DIAMETER
8.5.3. MARKET BY PATIENT DEMOGRAPHIC
8.5.4. MARKET BY APPLICATION
8.5.5. MARKET BY END-USER DIAMETER
8.5.6. COUNTRY ANALYSIS
8.5.6.1. UNITED ARAB EMIRATES
8.5.6.1.1. UNITED ARAB EMIRATES ARTIFICIAL
BLOOD VESSELS MARKET FORECAST & PROSPECTS
8.5.6.2. SAUDI ARABIA
8.5.6.2.1. SAUDI ARABIA ARTIFICIAL
BLOOD VESSELS MARKET FORECAST & PROSPECTS
8.5.6.3. ISRAEL
8.5.6.3.1. ISRAEL ARTIFICIAL BLOOD
VESSELS MARKET FORECAST & PROSPECTS
8.5.6.4. SOUTH AFRICA
8.5.6.4.1. SOUTH AFRICA ARTIFICIAL
BLOOD VESSELS MARKET FORECAST & PROSPECTS
8.5.6.5. REST OF MIDDLE EAST &
AFRICA
8.5.6.5.1. REST OF MIDDLE EAST &
AFRICA ARTIFICIAL BLOOD VESSELS MARKET FORECAST & PROSPECTS
9. COMPETITIVE LANDSCAPE
9.1. BECTON, DICKINSON AND COMPANY
9.1.1. OVERVIEW
9.1.2. PORTFOLIO
9.1.3. KEY STRENGTHS
9.1.4. KEY CHALLENGE
9.2. LEMAITRE VASCULAR INC
9.2.1. OVERVIEW
9.2.2. PORTFOLIO
9.2.3. KEY STRENGTHS
9.2.4. KEY CHALLENGE
9.3. MEDTRONIC PLC
9.3.1. OVERVIEW
9.3.2. PORTFOLIO
9.3.3. KEY STRENGTH
9.3.4. KEY CHALLENGE
9.4. TERUMO MEDICAL CORPORATION
9.4.1. OVERVIEW
9.4.2. PORTFOLIO
9.4.3. KEY STRENGTHS
9.4.4. KEY CHALLENGE
9.5. W. L. GORE AND ASSOCIATES INC
9.5.1. OVERVIEW
9.5.2. PORTFOLIO
9.5.3. KEY STRENGTHS
9.5.4. KEY CHALLENGES
9.6. GETINGE AB
9.6.1. OVERVIEW
9.6.2. PORTFOLIO
9.6.3. KEY STRENGTHS
9.6.4. KEY CHALLENGE
9.7. ROUMAI MEDICAL
9.7.1. OVERVIEW
9.7.2. PORTFOLIO
9.7.3. KEY STRENGTHS
9.7.4. KEY CHALLENGES
9.8. MEDICALEXPO
9.8.1. OVERVIEW
9.8.2. PORTFOLIO
9.8.3. KEY STRENGTHS
9.8.4. KEY CHALLENGES
9.9. VASCULAR GRAFT SOLUTIONS
9.9.1. OVERVIEW
9.9.2. PORTFOLIO
9.9.3. KEY STRENGTHS
9.9.4. KEY CHALLENGES
9.10. JIANGSU BIODA LIFE SCIENCE CO LTD
9.10.1. OVERVIEW
9.10.2. PORTFOLIO
9.10.3. KEY STRENGTHS
9.10.4. KEY CHALLENGE
10. RESEARCH METHODOLOGY & SCOPE
10.1. RESEARCH SCOPE & DELIVERABLES
10.2. SOURCES OF DATA
10.3. RESEARCH METHODOLOGY
TABLE 1: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY REGIONAL OUTLOOK,
HISTORICAL YEARS, 2020-2023 (IN $ MILLION)
TABLE 2: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY REGIONAL OUTLOOK,
FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 3: REGULATORY FRAMEWORK
TABLE 4: LIST OF COLLABORATIONS
TABLE 5: LIST OF PRODUCT LAUNCHES
TABLE 6: LIST OF ACQUISITIONS
TABLE 7: LIST OF BUSINESS DIVESTITURES & EXPANSIONS
TABLE 8: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY TYPE, 2024-2032 (IN
$ MILLION)
TABLE 9: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY BLOOD VESSEL
DIAMETER, 2024-2032 (IN $ MILLION)
TABLE 10: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY PATIENT
DEMOGRAPHIC, 2024-2032 (IN $ MILLION)
TABLE 11: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY APPLICATION,
2024-2032 (IN $ MILLION)
TABLE 12: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY END-USER, 2024-2032
(IN $ MILLION)
TABLE 13: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY REGIONAL OUTLOOK,
HISTORICAL YEARS, 2020-2023 (IN $ MILLION)
TABLE 14: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY REGIONAL OUTLOOK,
FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 15: NORTH AMERICA ARTIFICIAL BLOOD VESSELS MARKET, BY COUNTRY
OUTLOOK, 2024-2032 (IN $ MILLION)
TABLE 16: NORTH AMERICA ARTIFICIAL BLOOD VESSELS MARKET, BY TYPE,
2024-2032 (IN $ MILLION)
TABLE 17: NORTH AMERICA ARTIFICIAL BLOOD VESSELS MARKET, BY BLOOD VESSEL
DIAMETER, 2024-2032 (IN $ MILLION)
TABLE 18: NORTH AMERICA ARTIFICIAL BLOOD VESSELS MARKET, BY PATIENT
DEMOGRAPHIC, 2024-2032 (IN $ MILLION)
TABLE 19: NORTH AMERICA ARTIFICIAL BLOOD VESSELS MARKET, BY APPLICATION,
2024-2032 (IN $ MILLION)
TABLE 20: NORTH AMERICA ARTIFICIAL BLOOD VESSELS MARKET, BY END-USER,
2024-2032 (IN $ MILLION)
TABLE 21: EUROPE ARTIFICIAL BLOOD VESSELS MARKET, BY COUNTRY OUTLOOK,
2024-2032 (IN $ MILLION)
TABLE 22: EUROPE ARTIFICIAL BLOOD VESSELS MARKET, BY TYPE, 2024-2032 (IN
$ MILLION)
TABLE 23: EUROPE ARTIFICIAL BLOOD VESSELS MARKET, BY BLOOD VESSEL
DIAMETER, 2024-2032 (IN $ MILLION)
TABLE 24: EUROPE ARTIFICIAL BLOOD VESSELS MARKET, BY PATIENT
DEMOGRAPHIC, 2024-2032 (IN $ MILLION)
TABLE 25: EUROPE ARTIFICIAL BLOOD VESSELS MARKET, BY APPLICATION,
2024-2032 (IN $ MILLION)
TABLE 26: EUROPE ARTIFICIAL BLOOD VESSELS MARKET, BY END-USER, 2024-2032
(IN $ MILLION)
TABLE 27: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY COUNTRY
OUTLOOK, 2024-2032 (IN $ MILLION)
TABLE 28: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY TYPE,
2024-2032 (IN $ MILLION)
TABLE 29: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY BLOOD VESSEL
DIAMETER, 2024-2032 (IN $ MILLION)
TABLE 30: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY PATIENT
DEMOGRAPHIC, 2024-2032 (IN $ MILLION)
TABLE 31: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY APPLICATION,
2024-2032 (IN $ MILLION)
TABLE 32: ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET, BY END-USER,
2024-2032 (IN $ MILLION)
TABLE 33: LATIN AMERICA ARTIFICIAL BLOOD VESSELS MARKET, BY COUNTRY
OUTLOOK, 2024-2032 (IN $ MILLION)
TABLE 34: LATIN AMERICA ARTIFICIAL BLOOD VESSELS MARKET, BY TYPE,
2024-2032 (IN $ MILLION)
TABLE 35: LATIN AMERICA ARTIFICIAL BLOOD VESSELS MARKET, BY BLOOD VESSEL
DIAMETER, 2024-2032 (IN $ MILLION)
TABLE 36: LATIN AMERICA ARTIFICIAL BLOOD VESSELS MARKET, BY PATIENT
DEMOGRAPHIC, 2024-2032 (IN $ MILLION)
TABLE 37: LATIN AMERICA ARTIFICIAL BLOOD VESSELS MARKET, BY APPLICATION,
2024-2032 (IN $ MILLION)
TABLE 38: LATIN AMERICA ARTIFICIAL BLOOD VESSELS MARKET, BY END-USER,
2024-2032 (IN $ MILLION)
TABLE 39: MIDDLE EAST AND AFRICA ARTIFICIAL BLOOD VESSELS MARKET, BY
COUNTRY OUTLOOK, 2024-2032 (IN $ MILLION)
TABLE 40: MIDDLE EAST AND AFRICA ARTIFICIAL BLOOD VESSELS MARKET, BY
TYPE, 2024-2032 (IN $ MILLION)
TABLE 41: MIDDLE EAST AND AFRICA ARTIFICIAL BLOOD VESSELS MARKET, BY
BLOOD VESSEL DIAMETER, 2024-2032 (IN $ MILLION)
TABLE 42: MIDDLE EAST AND AFRICA ARTIFICIAL BLOOD VESSELS MARKET, BY
PATIENT DEMOGRAPHICS, 2024-2032 (IN $ MILLION)
TABLE 43: MIDDLE EAST AND AFRICA ARTIFICIAL BLOOD VESSELS MARKET, BY
APPLICATION, 2024-2032 (IN $ MILLION)
TABLE 44: MIDDLE EAST AND AFRICA ARTIFICIAL BLOOD VESSELS MARKET, BY
END-USER, 2024-2032 (IN $ MILLION)
FIGURE 1: MARKET MATURITY ANALYSIS
FIGURE 2: SUPPLY CHAIN ANALYSIS
FIGURE 3: KEY BUYING IMPACT ANALYSIS
FIGURE 4: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY TYPE, 2023 &
2032 (IN %)
FIGURE 5: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY EXPANDED POLYTETRAFLUOROETHYLENE
(EPTFE), 2024-2032 (IN $ MILLION)
FIGURE 6: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY POLYETHYLENE
TEREPHTHALATE (PET), 2024-2032 (IN $ MILLION)
FIGURE 7: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY POLYURETHANE,
2024-2032 (IN $ MILLION)
FIGURE 8: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY OTHER TYPES,
2024-2032 (IN $ MILLION)
FIGURE 9: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY BLOOD VESSEL
DIAMETER, 2023 & 2032 (IN %)
FIGURE 10: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY LARGE, 2024-2032
(IN $ MILLION)
FIGURE 11: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY MEDIUM, 2024-2032
(IN $ MILLION)
FIGURE 12: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY SMALL, 2024-2032
(IN $ MILLION)
FIGURE 13: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY PATIENT
DEMOGRAPHIC, 2023 & 2032 (IN %)
FIGURE 14: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY PEDIATRIC,
2024-2032 (IN $ MILLION)
FIGURE 15: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY ADULT, 2024-2032
(IN $ MILLION)
FIGURE 16: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY APPLICATION, 2023
& 2032 (IN %)
FIGURE 17: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY PERIPHERAL ARTERY,
2024-2032 (IN $ MILLION)
FIGURE 18: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY HEMODIALYSIS,
2024-2032 (IN $ MILLION)
FIGURE 19: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY AORTIC DISEASE,
2024-2032 (IN $ MILLION)
FIGURE 20: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY END-USER, 2023
& 2032 (IN %)
FIGURE 21: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY HOSPITAL, 2024-2032
(IN $ MILLION)
FIGURE 22: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY SPECIALTY CLINIC,
2024-2032 (IN $ MILLION)
FIGURE 23: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY ONLINE PHARMACY,
2024-2032 (IN $ MILLION)
FIGURE 24: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY OTHER END-USERS,
2024-2032 (IN $ MILLION)
FIGURE 25: GLOBAL ARTIFICIAL BLOOD VESSELS MARKET, BY REGIONAL OUTLOOK,
2023 & 2032 (IN %)
FIGURE 26: UNITED STATES ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $
MILLION)
FIGURE 27: CANADA ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $
MILLION)
FIGURE 28: UNITED KINGDOM ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $
MILLION)
FIGURE 29: GERMANY ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $
MILLION)
FIGURE 30: FRANCE ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $
MILLION)
FIGURE 31: SPAIN ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $ MILLION)
FIGURE 32: ITALY ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $ MILLION)
FIGURE 33: POLAND ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $
MILLION)
FIGURE 34: REST OF EUROPE ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $
MILLION)
FIGURE 35: CHINA ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $ MILLION)
FIGURE 36: JAPAN ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $ MILLION)
FIGURE 37: INDIA ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $ MILLION)
FIGURE 38: SOUTH KOREA ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $
MILLION)
FIGURE 39: ASEAN COUNTRIES ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN
$ MILLION)
FIGURE 40: AUSTRALIA & NEW ZEALAND ARTIFICIAL BLOOD VESSELS MARKET
2024-2032 (IN $ MILLION)
FIGURE 41: REST OF ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET 2024-2032
(IN $ MILLION)
FIGURE 42: BRAZIL ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $
MILLION)
FIGURE 43: MEXICO ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $ MILLION)
FIGURE 44: REST OF LATIN AMERICA ARTIFICIAL BLOOD VESSELS MARKET
2024-2032 (IN $ MILLION)
FIGURE 45: UNITED ARAB EMIRATES ARTIFICIAL BLOOD VESSELS MARKET 2024-2032
(IN $ MILLION)
FIGURE 46: SAUDI ARABIA ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $
MILLION)
FIGURE 47: ISRAEL ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $
MILLION)
FIGURE 48: SOUTH AFRICA ARTIFICIAL BLOOD VESSELS MARKET 2024-2032 (IN $
MILLION)
FIGURE 49: REST OF MIDDLE EAST & AFRICA ARTIFICIAL BLOOD VESSELS
MARKET 2024-2032 (IN $ MILLION)